Medtronic R&D Engineer Joseph Hirsch highlights a key career distinction. "New product" focuses on initial design and FDA approval, while "sustaining" engineering supports launched products, manages manufacturing changes, and secures regulatory approval for global markets.

For new medical technologies to be adopted in over-burdened systems like the NHS, proof of efficacy in a lab is insufficient. The 'real acid test' is demonstrating that the technology works on the front lines of a busy, complex hospital. This real-world evidence is essential for gaining buy-in from skeptical staff.

Many firms view patient engagement as a compliance task that adds cost. However, data shows integrating patient experience into development from the start speeds up clinical trial recruitment and execution, reduces FDA amendments, and accelerates time-to-market, providing clear ROI.

Beyond establishing safety and efficacy, first-in-human trials provide crucial, practical insights unavailable from preclinical models. They reveal how a product fits into real surgical practice: if it's easy for surgeons to use, integrates into existing procedures, and requires additional training. This real-world validation is invaluable.

By releasing new software features weekly based on direct feedback from surgeons in the clinic, Andromeda has compressed the typical multi-year MedTech development cycle into weeks. This rapid, customer-centric improvement loop is shocking to the traditionally slow-moving medical industry.

The next wave of MedTech innovation won't just come from engineers. It will come from creating tools that allow surgeons and clinicians—those who see problems firsthand—to easily prototype and de-risk new device concepts, vastly expanding the market for innovation itself.

The most critical role for a physician co-founder extends beyond the initial idea. They must act as the primary evangelist and validator, sharing the engineering progress with their peers to ensure the device's design and function align with the broader clinical community's needs and vision.

Negative clinical trial results should not be seen as complete failures. Dr. Adam Arthur explains that even when an intervention fails its primary goal, the data provides crucial learnings that redirect research toward more promising pathways for patient care.

At American Housing Corp, engineers who design components also manufacture them in the factory and assemble them in the field. This forces them to experience the "pain" of their design decisions firsthand, creating a rapid, visceral feedback loop that leads to faster and more effective product improvements.